← 返回前沿论文

编织 NK 细胞抗肿瘤免疫反应的转录网络

英文原题:Transcriptional networks weaving natural killer anti-tumor immune response.

PubMed 2026/03/11(内容时间) Mol Cancer Q1 · IF 42.2(JCR 2025)

研究概要

考虑到转录因子在调控NK功能中的相关性,通过药理学方法或基因组编辑将其潜在开发为新型治疗靶点,是癌症治疗的新机遇。

研究思路结论见上方概要

NK 细胞(NKs)是固有免疫监视的关键效应细胞,无需预先抗原致敏即可清除靶细胞。NKs在肿瘤免疫中的关键作用已在血液系统肿瘤和实体瘤中受到广泛关注。此外,基于NK的细胞疗法因其现货型可用性和较低的毒性风险,已成为T细胞疗法之外极具吸引力的替代选择。然而,驱动NK在不同肿瘤背景下抗肿瘤疗效的内在分子机制仍鲜有描述,严重阻碍了其临床应用。

本综述旨在全面概述定义NK抗肿瘤反应各步骤的转录网络,从组织募集到靶标识别和细胞毒性激活。同时从转录角度重点阐述在肿瘤微环境中触发NK功能障碍的分子机制。所描述的时间依赖性和环境依赖性转录机制的特征是激活因子与抑制因子之间的持续相互作用,这种相互作用整合并平衡来自周围肿瘤生态系统的信号。

展开英文摘要原文

BACKGROUND: Natural killer cells (NKs) are critical effectors of innate immune surveillance, capable of eliminating target cells without prior antigen sensitization. The crucial role of NKs in cancer immunity has largely been highlighted in both hematological and solid tumors. Besides, NK-based cell therapies have gained momentum as a compelling alternative to T cell-based approaches, due to their off-the-shelf availability and lower risk of toxicity. Still, the intrinsic molecular mechanisms driving NK anti-tumor efficacy in different tumor contexts are poorly described, drastically impairing their clinical exploitation. AIMS: This review aims to provide a comprehensive overview of the transcriptional networks defining each step of NK anti-tumor response, from tissue recruitment to target recognition and cytotoxic activation. The molecular mechanisms triggering NK dysfunction in the tumor microenvironment are also highlighted from a transcriptional perspective. The described time- and context-dependent transcriptional machinery is characterized by a constant interplay between activators and repressors, which integrates and balances signals deriving from the surrounding tumor ecosystem. CONCLUSIONS: Considering the relevance of transcription factors in controlling NK functions, their potential exploitation as novel therapeutic targets, through either pharmacological approaches or genome editing, is a new opportunity for cancer treatment.

论文信息

作者
Redavid AR、Bigliardi M、Ciarrocchi A、Reggiani F
第一作者单位
Translational Research Laboratory, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, 42123, Italy.Italy
通讯作者单位
Translational Research Laboratory, Azienda USL-IRCCS di Reggio Emilia, Viale Risorgimento 80, Reggio Emilia, 42123, Italy. francesca.reggiani2@ausl.re.it.Italy
文献类型
综述
期刊
Molecular cancer2026 Mar 11
原文标识
PubMed 41814366 · DOI 10.1186/s12943-026-02643-4